RVMDPhase 2 Readout
RAS(ON) inhibitor expansion cohort update
Revolution Medicines | RMC-6236 | Pancreatic ductal adenocarcinoma
Catalyst details
Investor-tracked clinical update for RAS-mutant solid tumors.
Phase
Phase 2
Expected date
2026-07-10
Expected period
July 2026
Source type
manual
monthactive
Source URLNotes
This record is structured for public-source tracking and manual analyst override. The database stores date confidence separately from exact dates so quarter, half-year, and estimated guidance can be handled without inventing precision.
Open company detail